The U.S. ophthalmic drugs market size was estimated at USD 15.53 billion in 2023 and is anticipated to grow at a CAGR of 7.4% from 2024 to 2030. The steady growth in the aging population in the country, coupled with an increasing prevalence of eye-related disorders among adults and children, is expected to remain a significant contributing factor to the demand for ophthalmic drugs. As per the 2022 National Health Interview Survey estimates, over 50 million Americans aged 18 years and above stated that they experienced vision loss with varying degrees. Among this demographic, around four million people claimed to have significant vision issues while wearing glasses, while 340,000 stated that they could not see at all.
The U.S. market for ophthalmic drugs accounted for a revenue share of 41.1% in the global ophthalmic drug market in 2023. The increasing incidence of diabetes among the population due to sedentary and unhealthy lifestyle patterns has increased the risk of diabetic retinopathy (DR), leading to a significant demand for medications. Age-related macular degeneration (AMD) is another common disorder among American adults, with one in every 10 Americans aged 50 and older having an early form of AMD and one out of every 100 Americans having the vision-threatening late form of AMD. According to an article published by BrightFocus Foundation, around 20 million adults in the country had some form of AMD, with recent studies showing that growth in the prevalence of this disorder has been around twice the previous estimation. The condition worsens with age and thus requires diagnosis at the earliest possible instance to provide more effective treatment.
Key U.S. Ophthalmic Drugs Company Insights
Some of the major companies in the U.S. market for ophthalmic drugs include Pfizer, Alcon, Regeneron Pharmaceuticals, and Nicox Ophthalmics.
- Alcon, operationally headquartered in Fort Worth, Texas, offers products for treating disorders of the eyes and vision, specifically cataracts, refractive errors, vitreoretinal, and other ocular health disorders. The company offers a wide variety of solutions in vision care & ophthalmic surgery, including contact lenses & solutions, eye care products, cataract surgery solutions, LASIK, refractive technology, and vitreoretinal surgery. Alcon offers both OTC drugs (SYSTANE, GenTeal Tears, Naphcon-A, and Pataday) and prescription drugs (Rhopressa, SIMBRINZA, and INVELTYS) to address eye disorders in consumers
U.S. Ophthalmic Drugs Market Segmentation
This report forecasts revenue growth at the country level and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. ophthalmic drugs market report based on drug class, disease, route of administration, dosage form, type, and product:
- Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
- Anti-allergy
- Anti-inflammatory
- Non-steroidal drugs
- Steroidal drugs
- Anti-VEGF Agents
- Anti-glaucoma
- Gene & Cell Therapy
- Others
- Disease Outlook (Revenue, USD Million, 2018 - 2030)
- Dry Eye
- Gels
- Eye Solutions & Suspensions
- Capsules & Tablets
- Eye Drops
- Ointments
- Allergies
- Gels
- Eye Solutions & Suspensions
- Capsules & Tablets
- Eye Drops
- Ointments
- Glaucoma
- Gels
- Eye Solutions & Suspensions
- Capsules & Tablets
- Eye Drops
- Ointments
- Eye Infection
- Gels
- Eye Solutions & Suspensions
- Capsules & Tablets
- Eye Drops
- Ointments
- Retinal Disorders
- Retinal Disorder Treatment Market, By Type
- Macular Degeneration
- Diabetic Retinopathy
- Others
- Retinal Disorder Treatment Market, By Dosage Type
- Gels
- Eye Solutions & Suspensions
- Capsules & Tablets
- Eye Drops
- Ointments
- Uveitis
- Gels
- Eye Solutions & Suspensions
- Capsules & Tablets
- Eye Drops
- Ointments
- Others
- Retinal Disorder Treatment Market, By Type
- Dosage Form Outlook (Revenue, USD Million, 2018 - 2030)
- Gels
- Eye Solutions & Suspensions
- Capsules and Tablets
- Eye Drops
- Ointments
- Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
- Topical
- Local Ocular
- Subconjunctival
- Intravitreal
- Retrobulbar
- Intracameral
- Systemic
- Type Outlook (Revenue, USD Million, 2018 - 2030)
- Prescription Drugs
- OTC
- Product Outlook (Revenue, USD Million, 2018 - 2030)
- Branded Drugs
- Generic Drugs
- Dry Eye
Curious about the U.S. Ophthalmic Drugs Market? Download your FREE sample copy now and get a sneak peek into the latest insights and trends.
Key U.S. Ophthalmic Drugs Companies:
- Pfizer Inc.
- Novartis AG
- Alcon
- Bausch Health Companies Inc.
- Merck & Co., Inc.
- Regeneron Pharmaceuticals Inc.
- AbbVie Inc.
- Bayer Corporation
- Genentech, Inc.
- Nicox Ophthalmics, Inc.
- Coherus BioSciences
Recent Developments
- In May 2024, Regeneron Pharmaceuticals presented positive long-term results, as well as subgroup analyses, from the clinical program of EYLEA HD (aflibercept) Injection 8 mg at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) held in Seattle. EYLEA HD has been indicated for patients living with diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration
- In March 2024, Sandoz announced that it acquired the U.S. biosimilar CIMERLI (ranibizumab-eqrn) from Coherus BioSciences, Inc. The acquisition is expected to help Sandoz expand its biosimilar portfolio and strengthen its ophthalmic platform in the country. The product addresses certain retinal disorders that can lead to vision loss if left untreated, which is a leading cause of disability in the U.S.
- In January 2024, Nicox SA announced that it received confirmation for a 5-year patent term extension for latanoprostene bunod’s U.S. patent. This is a pharmaceutical active ingredient developed and patented by Nicox and used in VYZULTA, commercialized by Bausch + Lomb, which is indicated for reducing intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma
Order a free sample PDF of the U.S. Ophthalmic Drugs Market Intelligence Study, published by Grand View Research.
